ReviewFrontiers in aging2025
Geranylgeranoic acid and the MAOB-CYP3A4 axis: a metabolic shift underlying age-related liver cancer risk.
Review in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prenols and prenoic acids in metabolism, disease, and aging.Journal of lipid research · 2026Review
- TNFAIP1 suppresses hepatocellular carcinoma progression via the PXR/CYP3A4 signaling axis.American journal of cancer research · 2026Article
- Geranylgeranoic acid, toll-like receptor 4, and pyroptosis-related signaling in hepatocellular carcinoma: a hypothesis-generating perspective.Oncology reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Geranylgeranoic acid (GGA) is a naturally occurring acyclic isoprenoid with chemopreventive effects against hepatocellular carcinoma. In mammals, GGA is endogenously synthesized via the oxidative metabolism of geranylgeraniol by monoamine oxidase B (MAOB). However, MAOB activity decreases with age, leading to reduced hepatic GGA levels. Emerging evidence suggests that cytochrome P450 3A4 (CYP3A4) may compensate for this decline, providing an alternative oxidative pathway in MAOB-deficient conditions. This mini-review summarizes the current findings on GGA biosynthesis and metabolism in the aging liver, focusing on the MAOB-CYP3A4 axis, in which MAOB serves as the primary enzyme for endogenous GGA synthesis and CYP3A4 provides a compensatory pathway under MAOB-deficient conditions, and its relevance to age-related hepatic dysfunction. By discussing recent evidence on enzymatic compensation and age-dependent metabolic changes, this review highlights how the CYP3A4-GGA pathway may help unravel the complexity of hepatic aging. These findings may provide a mechanistic basis for developing preventive strategies targeting age-related hepatocarcinogenesis, particularly in older individuals with reduced MAOB-GGA activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.